Vaderis Therapeutics

Vaderis Therapeutics is a clinical-stage biotechnology company that develops targeted therapies for rare vascular diseases.

Health and bio

Funding rounds

1. August 11, 2026
   Series B+ · $152M
   GGoldman Sachs Alternatives (lead), TTCG Crossover (lead), DDroia Ventures, EEQT Life Sciences, KKalehua Capital, MMedicxi, OOmega Funds, PPerceptive Advisors
   Source: fundraisingfox.com
2. September 8, 2017
   Website created

Founders and team

• DP
  Damien Picard Founder
• NB
  Nicholas Benedict Founder

  LinkedIn
• PM
  Pierre Mezard Founder

  LinkedIn
• AN
  Azmi Nabulsi President & CEO
• DS
  Darryl Sleep Chief Medical Officer
• KZ
  Karen Zylberman Chief of Staff and Head of Business Operations

Investors

• DDroia Ventures
• EEQT Life Sciences
• GGoldman Sachs Alternativeslead investor
• KKalehua Capital
• MMedicxi
• OOmega Funds
• PPerceptive Advisors
• TTCG Crossoverlead investor

Companies like Vaderis Therapeutics

• SStorm Therapeutics$56M Series B+ · Apr 2026
• CComplement TherapeuticsSeries A · Apr 2023
• EEngrail Therapeutics$157M Series B+ · Mar 2024
• AAirNexis Therapeutics$200M Series A · Jan 2026
• CCity TherapeuticsSeries B+ · Aug 2026
• NNoema PharmaSeries B+ · Nov 2025

Other companies backed by Goldman Sachs Alternatives

• CCyera$400M Series B+ · Sep 2026
• HHarvey$550M Series B+ · Sep 2026
• SSocure$156M Series B+ · Aug 2026
• SSpectro Cloud$100M Series B+ · Aug 2026
• RRedwood Materials$550M Series B+ · Jul 2026
• AAlphaSense$350M Series B+ · Jun 2026

Goldman Sachs Alternatives portfolio →